Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Cancer Chemother Pharmacol. 2013 Nov;72(5):985-90. doi: 10.1007/s00280-013-2278-7. Epub 2013 Sep 1.
The aim of this study was to evaluate S-1 and oxaliplatin combination chemotherapy (SOX) in patients with refractory pancreatic cancer (PC).
Consecutive patients with advanced PC refractory to gemcitabine who were treated with oral S-1 (80 mg/m²) on days 1-14 and intravenous oxaliplatin (100 mg/m²) on day 1 every 3 weeks were studied retrospectively. The primary end point was the objective response rate (ORR). The secondary end points were progression-free survival (PFS), overall survival (OS), the disease control rate (DCR), and safety.
Between March 2009 and October 2011, 30 patients were treated with SOX, with a median of two courses (range 1-8). The ORR and DCR were 10.0 and 50.0 %, respectively. Median PFS and OS were 3.4 months (95 % confidence interval [CI] 1.3-5.3) and 5.0 months (95 % CI 3.4-7.4), respectively. The median PFS and OS were 5.6 and 9.1 months in patients receiving S-1 and oxaliplatin as a second-line treatment. Major grade 3 or 4 adverse events included neutropenia (10.0 %), anemia (3.3 %), and diarrhea (6.7 %).
SOX was well tolerated and moderately effective in patients with refractory PC.
本研究旨在评估 S-1 和奥沙利铂联合化疗（SOX）在难治性胰腺癌（PC）患者中的疗效。
回顾性分析了 2009 年 3 月至 2011 年 10 月期间，30 例接受吉西他滨治疗后进展的晚期难治性 PC 患者，采用 S-1（80mg/m²）口服，第 1-14 天；奥沙利铂（100mg/m²）静脉滴注，第 1 天，每 3 周 1 次。主要终点为客观缓解率（ORR）。次要终点包括无进展生存期（PFS）、总生存期（OS）、疾病控制率（DCR）和安全性。
30 例患者接受 SOX 治疗，中位治疗周期数为 2 个（范围 1-8 个）。ORR 和 DCR 分别为 10.0%和 50.0%。中位 PFS 和 OS 分别为 3.4 个月（95%CI 1.3-5.3）和 5.0 个月（95%CI 3.4-7.4）。在接受 S-1 和奥沙利铂二线治疗的患者中，中位 PFS 和 OS 分别为 5.6 和 9.1 个月。主要的 3 级或 4 级不良事件包括中性粒细胞减少（10.0%）、贫血（3.3%）和腹泻（6.7%）。
SOX 治疗难治性 PC 患者耐受性良好，疗效中等。
